John Garvey, a Foley Private Equity & Venture Capital Partner, moderated this session with panelists Josh Hamermesh of Molecular Insight Pharmaceuticals, Inc. and Matt Karlyn of Foley. They addressed in-licensing technology, specifically how to identify potential profit opportunities; approaching potential business partners, pre-transaction due diligence; negotiating with the licensor; and integration of the in-licensed technology into the company business operations.
Related Insights
December 9, 2025
Health Care Law Today
How Following “Doctors’ Orders” Provided a Defense in a First Circuit FCA Case
When it comes to False Claims Act (FCA) litigation, clinical laboratories often find themselves in the crosshairs. But the First…
December 9, 2025
Foley Viewpoints
White House Orders Task Forces To Investigate Food Industry
Last month, we reported on the Department of Justice (“DOJ”) ramping up antitrust enforcement in the agriculture industry, including…
December 8, 2025
Foley Viewpoints
2026 Outlook: AI, IPOs, and the New “Normal” in Venture & Private Equity
Key Takeaways The 2026 outlook for market activity is cautiously optimistic amid ongoing challenges.Private equity firms are shifting to…